Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Marts 2021

Planlagt Fastgjort Låst Flyttet Genmab
1.5k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • JørgenVarnæsJ Offline
    JørgenVarnæsJ Offline
    JørgenVarnæs
    wrote on sidst redigeret af
    #984

    In the end, I think the whole thing was written off - and the sales amount was very close to zero. The real cost was the diversion from the core business of Genmab - development of new drugs

    1 Reply Last reply
    0
    • JørgenVarnæsJ Offline
      JørgenVarnæsJ Offline
      JørgenVarnæs
      wrote on sidst redigeret af
      #985

      Purchase price usd 240m - sales price usd 10m....

      1 Reply Last reply
      0
      • JørgenVarnæsJ Offline
        JørgenVarnæsJ Offline
        JørgenVarnæs
        wrote on sidst redigeret af
        #986

        ...there is a hole in that business model, but I can’t seem to put my finger on it....

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #987

          well then let me say it in a different way, the buyer probably made a lot of money...

          1 Reply Last reply
          0
          • JørgenVarnæsJ Offline
            JørgenVarnæsJ Offline
            JørgenVarnæs
            wrote on sidst redigeret af
            #988

            But I’m guessing the real lesson was Zalu falling flat on it’s stomach - hope we will not see similar things with the programs we retain ownership over in the years to come

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #989

              Agree - but at least zalu lives on in Amivantamab

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #990

                I think it is fair to expect a few failures in the years to come, like Enapotamab failed. The art will be to detect them early before they cost too much... disappointments happen, but Genmab's hit-ratio is high so far, making me realistically optimistic

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #991

                  (is that even a real term, realistically optimistic, or did i just make that up lol)

                  1 Reply Last reply
                  0
                  • O Offline
                    O Offline
                    Optimistus
                    wrote on sidst redigeret af
                    #992

                    @Stockbull 01:44, så havde M.Lykketoft måske alligevel ret dengang (-:

                    1 Reply Last reply
                    0
                    • JørgenVarnæsJ Offline
                      JørgenVarnæsJ Offline
                      JørgenVarnæs
                      wrote on sidst redigeret af
                      #993

                      The great thing about a diversified portfolio is the ability to soak up the shock effect from these failures.

                      1 Reply Last reply
                      0
                      • JørgenVarnæsJ Offline
                        JørgenVarnæsJ Offline
                        JørgenVarnæs
                        wrote on sidst redigeret af
                        #994

                        But times have changed - I don’t believe we will see phase 3 programs fail as epicly as we did 10 years ago with ie zalutumumab. Today it is more a question of bringing the programs to market before the competition

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #995

                          i agree

                          1 Reply Last reply
                          0
                          • JørgenVarnæsJ Offline
                            JørgenVarnæsJ Offline
                            JørgenVarnæs
                            wrote on sidst redigeret af
                            #996

                            In turn, for investors that means catching the programs around the time we see efficacy in phase 1/2

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #997

                              @Sukkeralf who knows what they'll make from Enapotamab years from now 😉 Teprotumumab was also thought to be dead... you have to be a bit lucky as well when someone else develops your oldies 😉

                              1 Reply Last reply
                              0
                              • S Offline
                                S Offline
                                Sukkeralf
                                wrote on sidst redigeret af
                                #998

                                The same goes for the IL8 compound - but it still has a long way to go. But still alive and kicking

                                1 Reply Last reply
                                0
                                • S Offline
                                  S Offline
                                  Sukkeralf
                                  wrote on sidst redigeret af
                                  #999

                                  We just need BergenBio to show the way for AXL - and then some small obscure biotech can licence Enapotamab for some smaller indications

                                  1 Reply Last reply
                                  0
                                  • V Offline
                                    V Offline
                                    Vitus
                                    wrote on sidst redigeret af
                                    #1000

                                    Ingen interesserer sig for Genmab idag....al interesse ligger hos Bavarian...

                                    1 Reply Last reply
                                    0
                                    • D Offline
                                      D Offline
                                      deleted-user
                                      wrote on sidst redigeret af
                                      #1001

                                      Kæmpe omsætning i luk-auktionen....

                                      1 Reply Last reply
                                      0
                                      • D Offline
                                        D Offline
                                        deleted-user
                                        wrote on sidst redigeret af
                                        #1002

                                        121.000 aktier - ca. 50 % af dagens omsætning

                                        1 Reply Last reply
                                        0
                                        • Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktørH Offline
                                          Helge_LarsenPI-redaktør
                                          wrote on sidst redigeret af
                                          #1003

                                          Fredagens aktier: Bavarian og Netcompany til tops på coronahåb https://www.proinvestor.com/investornyt/673303/fredagens-aktier-bavarian-og-netcompany-til-tops-pa-coronahab

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger